May 23, 2011 — Elixir Medical Corporation, a developer of product platforms combining state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE Mark for its DESyne Drug Eluting Coronary Stent System for the treatment of coronary artery disease.

May 23, 2011– A pooled analysis of the global Resolute clinical program presented today during a late-breaking clinical trials session at EuroPCR demonstrated the strong safety record of the Resolute drug-eluting stent (DES) from Medtronic Inc., across a wide variety of patient and lesion types.

May 23, 2011 - One-year results from the 278-patient multi-center, prospective, single-arm study conducted at 16 sites in Europe and Israel were presented today at the EuroPCR 2011 Congress in Paris. These results reinforce the outcomes observed with the "Next Generation" Presillon Plus (PioNIR) cobalt chromium bare metal stent systems at 9-month followup, which was the primary endpoint of the PioNIR study.

May 23, 2011 - A presentation about transcatheter aortic valve implantation (TAVI) at EuroPCR 2011 confirmed positive outcomes in patients receiving the CoreValve System from Medtronic Inc., across seven international clinical registries. The meta-analysis, undertaken by several leading international interventional cardiologists and presented during a late-breaking trial Hot Line session, summarized European data from 2,156 patients treated with the CoreValve System for severe aortic stenosis.

May 23, 2011 -- Boston Scientific Corporation announced results from a clinical study evaluating the use of its Watchman Left Atrial Appendage Closure Device in patients with atrial fibrillation who have a contraindication to oral anticoagulants such as warfarin. Data were presented at the annual EuroPCR Scientific Program in Paris by Martin Bergmann, M.D., Department of Cardiology at the Asklepios Klinik St. Georg in Hamburg, Germany, and principal Iinvestigator of the study.

May 20, 2011 - Boston Scientific Corporation today announced 12-month results from its PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25mm Promus Element Everolimus-Eluting Platinum Chromium Stent System in treating small vessel coronary disease. The study is a global, prospective, single-arm, subtrial of the PLATINUM clinical program. It compares the Promus Element Stent (2.25mm) in 94 patients with small vessels (greater than or equal to 2.25 to less than 2.50 mm reference vessel diameter and less than or equal to 28mm lesion length) to a pre-specified performance goal based on results from patients treated with the Taxus Express Paclitaxel-Eluting Stent.

May 20, 2011 – e-BioMatrix post-marketing surveillance (PMS) registry information presented at EuroPCR 2011 has confirmed that BioMatrix, Biosensors’ Biolimus A9-eluting stent system with abluminal bioresorbable polymer, is safe over a 12-month period in a “real-world” patient population.